IP Library Granted Patent US 8,546,548
Granted Patent B2
US 8,546,548 · App. 12/789,345 · Granted Oct 1, 2013

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,548
App. No.
12/789,345
Granted
Oct 1, 2013
Kind
B2
Abstract

The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.

Claims (36)

1. A method for preparing a concentrated immunoglobulin G (IgG) composition, comprising the steps:

(A) concentrating a first solution comprising IgG to a protein concentration of from 2% to 10% (w/v) by ultrafiltration using a first ultra-/diafiltration system comprising a first ultrafiltration membrane, thereby forming a first IgG concentrate;

(B) diafiltering the first IgG concentrate against a diafiltration buffer using the first ultra-diafiltration system comprising the first ultrafiltration membrane, thereby forming a first IgG diafiltrate;

(C) concentrating the first IgG diafiltrate to a protein concentration of greater than 20% (w/v) by ultrafiltration using the first ultra-/diafiltration system comprising the first ultrafiltration membrane, thereby forming a second IgG concentrate;

(D) collecting the second IgG concentrate from the first ultra-/diafiltration system;

(E) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system wherein the first ultra-/diafiltration system is washed with a volume of post-wash buffer equal to at least two times the dead volume of the first ultra-/diafiltration system, thereby forming a first IgG post-wash solution;

(F) transfering the first IgG post-wash solution from the first ultra-/diafiltration system into a second ultra-/diafiltration system comprising a second ultrafiltration membrane, wherein the surface area of the second ultrafiltration membrane is lower than the surface area of the first ultrafiltration membrane;

(G) concentrating the first IgG post-wash solution to a protein concentration of greater than 20% (w/v) by ultrafiltration using the second ultra-/diafiltration system comprising a second ultra-/diafiltration membrane, thereby forming a third IgG concentrate; and

(H) combining the third IgG concentrate from the second ultra-/diafiltration system with the second IgG concentrate, thereby forming a concentrated IgG composition.

2. The method of claim 1 , wherein the first solution comprising IgG is concentrated in (A) to a protein concentration of 5±1% (w/v).

3. The method of claim 1 , wherein the first ultrafiltation membrane is an open-screen membrane.

4. The method of claim 1 , wherein the first or second ultrafiltration membrane have a nominal molecular weight cut off (NMWCO) of 100 kDa or less.

5. The method of claim 1 , wherein the first and second ultrafiltration membrane has a nominal molecular weight cut off (NMWCO) of 100 kDa or less.

6. The method of claim 1 , wherein the first or second ultrafiltration membrane has a nominal molecular weight cut off (NMWCO) of 90 kDa or less.

7. The method of claim 1 , wherein the first and second ultrafiltration membrane have a nominal molecular weight cut off (NMWCO) of 90 kDa or less.

8. The method of claim 1 , wherein the first and second ultrafiltration membrane have a same nominal molecular weight cut off (NMWCO).

9. The method of claim 1 , wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2±0.1.

10. The method of claim 1 , wherein the second IgG concentrate has a protein concentration of at least 22% (w/v).

11. The method of claim 1 , wherein the surface area of the second ultrafiltration membrane is no more than a tenth of the surface area of the first ultrafiltration membrane.

12. The method of claim 1 , wherein the protein concentration of the concentrated IgG composition formed in (H) is greater than 20% (w/v), and wherein the method further comprises adjusting the concentration of the concentrated IgG composition formed in (H) to about 20% (w/v).

13. The method of claim 1 , wherein the pH of the concentrated IgG composition formed in (H) is from 4.0 to 6.0.

14. The method of claim 1 , further comprising the steps of:

(I) washing the second ultrafiltration membrane by re-circulating a post-wash buffer through the second ultra-/diafiltration system, thereby forming a second IgG post-wash solution; and

(J) adjusting the protein concentration of the concentrated IgG composition formed in (H) by admixing at least a portion of the second IgG post-wash solution into the concentrated IgG composition formed in (H).

15. The method of claim 1 , wherein the IgG is human IgG.

16. The method of claim 1 , comprising the steps:

(A) concentrating a first solution comprising IgG to a protein concentration of 5±1% (w/v) by ultrafiltration using a first ultra-/diafiltration system comprising a first ultrafiltration membrane, thereby forming a first IgG concentrate, the first ultrafiltration membrane having a NMWCO of 60 kDa or less;

(B) diafiltering the first IgG concentrate against a diafiltration buffer using the first ultra-/diafiltration system comprising the first ultrafiltration membrane, thereby forming a first IgG diafiltrate, the diafiltration buffer comprising glycine and a pH of 4.2±0.1;

(C) concentrating the first IgG diafiltrate to a protein concentration of greater than 20% (w/v) by ultrafiltration using the first ultra-/diafiltration system comprising the first ultrafiltration membrane, thereby forming a second IgG concentrate;

(D) collecting the second IgG concentrate from the first ultra-/diafiltration system;

(E) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby forming a first IgG post-wash solution, the post-wash buffer having a volume equal to at least two times the dead volume of the first ultra-/diafiltration system;

(F) collecting the first IgG post-wash solution from the first ultra-/diafiltration system into a second ultra-/diafiltration system comprising a second ultrafiltration membrane, the second ultrafiltration membrane having a NMWCO of 60 kDa or less;

(G) concentrating the first IgG post-wash solution to a protein concentration of greater than 20% (w/v) by ultrafiltration using the second ultra-/diafiltration system comprising a second ultra-/diafiltration membrane, wherein the surface area of the second ultrafiltration membrane is no more than a tenth of the surface area of the first ultrafiltration membrane, thereby forming a third IgG concentrate;

(H) combining the third IgG concentrate from the second ultra-/diafiltration system with the second IgG concentrate, thereby forming a concentrated IgG composition;

(I) washing the second ultrafiltration membrane by re-circulating a post-wash buffer through the second ultra-/diafiltration system, thereby forming a second IgG post-wash solution; and

(J) adjusting the protein concentration of the concentrated IgG composition formed in (H) by admixing at least a portion of the second IgG post-wash solution into the concentrated IgG composition formed in (H).

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTIES NAME PREVIOUSLY RECORDED AT REEL: 036360 FRAME: 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036621/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036360/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036372/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2010
From: TESCHNER, WOLFGANG; BUTTERWECK, HARALD ARNO; PLJEVLJAKOVIC, AZRA; BAUER, THERESA FRIEDERIKE; KOELBL, BERNHARD; SCHWARZ, HANS-PETER; NIKOLIC, NEBOJSA; POELSLER, GERHARD; KINDERMANN, JOHANNA
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 024978/0096 →